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Diabetes increases oxidant stress and doubles the risk of dying after myocardial infarction, but the mecha-
nisms underlying increased mortality are unknown. Mice with streptozotocin-induced diabetes developed 
profound heart rate slowing and doubled mortality compared with controls after myocardial infarction. Oxi-
dized Ca2+/calmodulin-dependent protein kinase II (ox-CaMKII) was significantly increased in pacemaker 
tissues from diabetic patients compared with that in nondiabetic patients after myocardial infarction. Strep-
tozotocin-treated mice had increased pacemaker cell ox-CaMKII and apoptosis, which were further enhanced 
by myocardial infarction. We developed a knockin mouse model of oxidation-resistant CaMKIIδ (MM-VV), 
the isoform associated with cardiovascular disease. Streptozotocin-treated MM-VV mice and WT mice infused 
with MitoTEMPO, a mitochondrial targeted antioxidant, expressed significantly less ox-CaMKII, exhibited 
increased pacemaker cell survival, maintained normal heart rates, and were resistant to diabetes-attributable 
mortality after myocardial infarction. Our findings suggest that activation of a mitochondrial/ox-CaMKII 
pathway contributes to increased sudden death in diabetic patients after myocardial infarction.
Introduction
Diabetes mellitus is a worldwide epidemic and a major public 
health problem that affects over 8% of the US population (1, 2). 
Myocardial infarction (MI) is the most common cause of mor-
tality in diabetics (3, 4), and multiple studies have shown that 
diabetic patients are twice as likely to die from MI compared 
with nondiabetic patients (2, 4–6). However, the mechanism(s) 
for the “diabetic factor” (7) underlying increased MI- related 
mortality in diabetic patients is unclear. Surprisingly, the excess 
mortality due to MI in diabetic patients is independent of com-
monly recognized comorbid clinical conditions, including the 
extent of myocardial injury, left ventricular contractile dys-
function, or coronary artery patency after reperfusion therapy 
(4–6, 8). Improved understanding of molecular mechanisms and 
pathways that promote death in diabetic patients after MI is a 
major goal of biomedical science.
ROS are elevated after MI (9, 10), and increased ROS promotes 
disease complications of diabetes (11, 12). However, broad-spec-
trum antioxidant therapies have yielded disappointing results (13), 
suggesting that detailed knowledge of oxidative injury mechanisms 
will be necessary to develop new and effective targeted antioxi-
dant therapies. The multifunctional Ca2+/calmodulin-dependent 
protein kinase II (CaMKII) is activated by oxidation (ox-CaMKII) 
(14), and ox-CaMKII may increase the risk of sudden death after 
MI by promoting heart failure (15), cardiac rupture (16), and 
arrhythmias (17). We found significantly more ox-CaMKII in dia-
betic hearts compared with that in nondiabetic hearts in patients 
who had MI, suggesting that ox-CaMKII could contribute to the 
increased mortality in diabetic patients after MI. Streptozotocin 
(STZ) is a pancreatic β cell toxin that induces a severe form of type I 
diabetes (18), and STZ-treated diabetic mice were twice as likely 
to die after MI surgery as vehicle-treated control mice, mimicking 
the increased mortality in diabetic patients compared with that in 
nondiabetic patients after MI. Oxidation of methionines 281/282 
in the CaMKII regulatory domain lock ox-CaMKII into a constitu-
tively active conformation (14). In order to test whether ox-CaMKII 
was an essential component of a molecular pathway that increased 
death in STZ-treated mice after MI, we created a knockin model of 
oxidation-resistant CaMKII by replacing the methionines 281/282 
with valines (MM-VV) in a myocardial CaMKII isoform (CaMKIIδ) 
known to participate in myocardial injury (19, 20). Diabetic, STZ-
treated MM-VV mice and mice with transgenic myocardial and 
sinoatrial nodal (SAN) pacemaker cell expression of a synthetic 
CaMKII inhibitory peptide (AC3-I) (21) were protected from 
increased mortality after MI, indicating that increased ox-CaMKII 
was essential for excess mortality after MI in STZ-treated mice.
Death in STZ-treated mice after MI was due to severe bradycardia, 
consistent with known defects in cardiac pacemaker function in dia-
betic patients (22–24) and recognized associations between abnor-
mal cardiac pacing and increased risk for sudden death (25). The 
increase in SAN ox-CaMKII expression in diabetes is likely a result of 
increased mitochondrial ROS triggered by hyperglycemia, as diabetic 
mice treated with a mitochondrial antioxidant, MitoTEMPO, showed 
reduced ox-CaMKII, preserved heart rates, and improved survival 
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after MI. Our findings are consistent with a pathway in which hyper-
glycemia enhances susceptibility to mortality after MI by increasing 
mitochondrial ROS, leading to excessive ox-CaMKII, SAN cell apop-
tosis, SAN dysfunction, and death. These results provide new insights 
into a novel mechanism underlying increased mortality in diabetes 
and MI and suggest that mitochondrial or CaMKII-targeted antioxi-
dant therapies could benefit high-risk diabetic patients.
Results
Diabetes increases MI mortality by SAN injury. STZ-treated mice had 
over a 2-fold increase in mean blood glucose compared with that of 
controls (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI65268DS1). Two to three 
weeks after STZ treatment, we performed MI surgery in STZ-in-
jected or vehicle-injected mice by ligating the left anterior descend-
ing coronary artery (15, 16, 21). Similar to diabetic patients (4–6), 
diabetic mice (WT) had significantly decreased survival after MI 
compared with that of nondiabetic mice (Figure 1A). However, 
there was no difference in survival after sham surgery between dia-
betic and nondiabetic mice (Supplemental Figure 2A), suggesting 
that the increased mortality in diabetic mice was due to MI. There 
were also no significant changes in serum chemistry (i.e., blood 
urea nitrogen or bicarbonate) to suggest ketoacidosis or acute renal 
failure as a potential cause of excessive mortality in STZ-treated 
mice (Supplemental Table 1). Most early deaths after MI are caused 
by heart failure due to depressed mechanical function (26), arrhyth-
mias (27), or myocardial rupture (28). To investigate the cause of 
the excessive acute death in diabetic mice after MI, we performed 
autopsies on all dead mice and found that 4 out of 5 deaths in 
nondiabetic mice were caused by cardiac rupture. In contrast, no 
rupture events were found in any STZ-treated diabetic mice. We 
performed echocardiography (2.1 ± 0.3 days in vehicle and 2.0 ± 0.4 
days in STZ group after MI) and found that there were no differ-
ences in left ventricular contractile function, chamber dilation 
(Supplemental Table 2), or in heart weight and lung weights nor-
malized to tibia length between the STZ-treated or control groups 
Figure 1
Increased death and SND in WT diabetic mice after MI. (A) Survival in WT mice treated with vehicle (Veh) (n = 10), STZ (n = 14), STZ and insulin 
(n = 7), and MitoTEMPO (Mito) and STZ (n = 11) and in AC3-I (n = 13), MM-VV (n = 19), and Ncf1–/– mice treated with STZ (n = 7) after MI. Overall 
P = 0.005 by 1-way ANOVA, P < 0.05 for comparisons between WT STZ and all other groups except the Ncf1–/– group (P = 0.7). (B–F) In vivo data from 
ECG-telemetered WT mice treated with vehicle, STZ, STZ and insulin, and MitoTEMPO and STZ and from AC3-I, MM-VV, and Ncf1–/– mice treated 
with STZ after MI (n = 4–14 per group). (B) Representative heart rate (HR) tracings ending in death. (C) Representative ECGs. Arrowheads indicate 
P waves. (D) Resting heart rates. Overall P < 0.0001, *P < 0.05, **P < 0.01, ***P < 0.001 by 1-way ANOVA. (E) Episodes of severe bradycardia (heart 
rate <200 beats per minute). Overall P = 0.0004, *P < 0.05, **P < 0.01, ***P < 0.001 by 1-way ANOVA. (F) Spontaneous activity-responsive heart rate 
(ARHR) increase (overall P = 0.001 for activity 1–10, P = 0.0005 for activity level 11–15, P = 0.0002 for all other activity levels by 1-way ANOVA).
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(Supplemental Table 1). There were also no significant differences 
in cardiac output (16 ± 1.5 ml/min in vehicle and 14 ± 0.7 ml/min in 
STZ group; P = 0.1) or left ventricular ejection fraction (76% ± 2.5% 
in vehicle and 76% ± 1.4% in STZ group; P = 0.8) prior to MI in dia-
betic mice compared with nondiabetic mice. These results suggest 
that intrinsic defects in the contractile function of surviving left 
ventricular myocardia of STZ-treated mice were not the primary 
cause of increased mortality after MI. However, echocardiographic 
studies did show that diabetic mice had decreased heart rates with-
out a significant change in left ventricular stroke volume, which 
caused significantly (P = 0.019) reduced cardiac output compared 
with that of the nondiabetic mice (Supplemental Table 2). These 
data pointed to a defect in SAN function as a potential determinant 
of increased mortality after MI in diabetic mice.
After MI, diabetic patients are at increased risk for sudden death 
due to cardiac arrhythmias (6, 29, 30), disorders of myocardial 
cell membrane excitability that result in excessively fast or slow 
heart rates. In order to investigate whether arrhythmia contrib-
utes to the excessive death in diabetic mice after MI, we contin-
uously monitored heart rate and rhythm in unrestrained and 
unanesthetized mice surgically implanted with ECG- and activity-
sensing telemeters. We measured ECGs immediately after recov-
ery from MI for up to 1 week or until death. Diabetic mice had 
marked heart rate slowing throughout the recording period, but 
heart rates slowed profoundly prior to death (Figure 1B, right). In 
contrast, deaths in vehicle-treated control mice after MI were not 
preceded by heart rate slowing (Figure 1B, left). The severe heart 
rate slowing was accompanied by reduced heart rate variability in 
diabetic mice compared with that in nondiabetic mice after MI 
(Figure 1B), similar to findings in high-risk diabetic patients (22, 
23). Analysis of the ECG traces showed slow heart rates emanating 
from the SAN, presumably due to defective SAN function, were 
the predominant cause of severe heart rate slowing (Figure 1C). 
WT diabetic mice after MI exhibited a significant reduction in 
heart rate at rest compared with that of vehicle-treated MI con-
trols (Figure 1D) and suffered frequent episodes of severe heart 
rate slowing, below 200 beats per minute, after MI (Figure 1E). 
In contrast, heart rate slowing events below 200 beats per minute 
were rarely detected in vehicle-treated mice after MI (Figure 1E). 
Furthermore, WT diabetic mice after MI had reduced heart rate 
responses to activity compared with those of vehicle-treated con-
trol mice after MI (Figure 1F), whereas both groups showed a sim-
ilar distribution of spontaneous activity throughout the recording 
period (Supplemental Figure 3). We did not identify episodes of 
abnormal rapid rhythms in any of the mice. These findings are 
consistent with features of severe SAN dysfunction (SND), slow 
resting heart rates and inadequate activity-related increases in 
heart rate. These findings are also consistent with known defects 
in cardiac pacemaker and autonomic nerve function in diabetic 
patients that are thought to cause reduced heart rate variability 
and prevent activity-related increases in heart rate (22, 23, 31). 
Thus, we interpreted our findings up to this point to suggest that 
SND, due to defects in SAN cells, autonomic activity, or both, con-
tributes to increased mortality after MI in diabetic mice.
In vivo heart rate is determined by intrinsic SAN automaticity 
under extrinsic modulation by autonomic nerves (32). In order 
to examine the mechanism of SND, we first asked whether STZ- 
induced diabetes in the absence of MI was sufficient to cause SND 
Figure 2
Intrinsic SND in diabetic mice. Langendorff-perfused hearts from WT mice treated with vehicle, STZ, and MitoTEMPO and STZ and AC3-I, 
MM-VV, and Ncf1–/– mice treated with STZ. (A) Heart rate. Overall P < 0.0001, ***P < 0.001 by 1-way ANOVA (n = 6–15 per group). (B) 
CSNRT. Overall P = 0.0003, **P < 0.01, *P < 0.05 by 1-way ANOVA (n = 5–8 per group). (C) Response to isoproterenol. *P < 0.0001 for 0 nM, 
**P = 0.0009 for 2 nM, ***P = 0.0001 for 20 nM, #P = 0.002 for 40 nM, ##P < 0.0001 for 100 nM (n = 5–8 per group). (D–F) Langendorff- perfused 
hearts isolated from STZ-treated mice after SAN painting with adenovirus expressing CaMKIIN and GFP or GFP alone. (D) Heart rates 
(*P = 0.01; n = 6–7 per group). (E) CSNRT (*P = 0.04; n = 6 per group). (F) Responses to isoproterenol (P > 0.05 for all doses excluding 100 nM, 
*P < 0.05; n = 6–7 per group).
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and whether SND was evident under conditions in which auto-
nomic regulation was absent. We measured heart rates in ex vivo, 
Langendorff-perfused hearts and in atrial explants that contained 
the SAN region isolated from diabetic and nondiabetic mice. Heart 
rates were significantly slower in WT diabetic hearts compared 
with those in nondiabetic counterparts (Figure 2A). We measured 
the sinus node recovery time corrected for heart rate (CSNRT), a 
clinical index of SAN function (33), in the Langendorff-perfused 
hearts. The CSNRT was significantly prolonged in WT diabetic 
mice compared with that in nondiabetic mice (Figure 2B). Fur-
thermore, hearts isolated from WT STZ-treated mice also showed 
impaired responses to isoproterenol (Figure 2C).
An advantage of the STZ model of type I diabetes is that it 
allowed us to focus on hyperglycemia as an upstream cause of 
increased mortality after MI. In order to test whether the increase in 
mortality and SND in our STZ and MI model was specifically due 
to hyperglycemia, we treated WT STZ and MI mice with insulin, 
which corrected STZ-induced hyperglycemia (Supplemental Figure 
1). We confirmed that increased mortality after MI required hyper-
glycemia, because mortality after MI was reduced to control levels 
by insulin replacement (Figure 1A). WT STZ-treated mice rescued 
by exogenous insulin were resistant to SND, showing improved 
resting (Figure 1D) and activity-induced heart rate increases (Fig-
ure 1F). These findings suggest that hyperglycemia alone is suffi-
cient to increase mortality after MI and show that potential off- 
target actions of STZ are unlikely to contribute to SND.
ox-CaMKII is increased in diabetic patients and STZ-treated mice. 
Increased ROS is a consistent feature of diabetes and is thought 
to contribute to diabetic heart disease (11). We recently identified 
CaMKII as an oxidant sensor (15–17) and found that excessive SAN 
Figure 3
Increased ox-CaMKII in diabetic patients and mice. (A) Representative immunoblots from right atrial tissues obtained from patients with or without 
diabetes mellitus and with MI. Band intensity was normalized to Coomassie staining. Summary data show CaMKII (P = 0.7), ox-CaMKII (*P = 0.02), 
and ox-CaMKII/CaMKII (**P = 0.03) in patients with diabetes mellitus (DM) and MI (n = 5) and MI alone (n = 5). Lanes were run on the same gel but 
were noncontiguous. (B) Representative immunoblots from right atria tissue obtained from STZ- or vehicle-treated mice. Summary data show CaMKII 
(P = 0.3), ox-CaMKII (*P = 0.04), and ox-CaMKII/CaMKII (*P = 0.04) in STZ- (n = 5) and vehicle-treated mice (n = 4). Lanes were run on the same gel 
but were noncontiguous. Band intensity was normalized to Coomassie staining. (C) Representative immunofluorescence images in SAN from mice 
treated with vehicle or STZ. HCN4 (green) marks SAN, and DAPI (blue) marks nuclei. Scale bars: 50 μm. Summary data show CaMKII (P = 0.8) 
and ox-CaMKII (**P = 0.005) in STZ- (n = 5) and vehicle-treated mice (n = 3). (D) Ca2+/calmodulin-independent autonomous activity (*P = 0.03, 
left), full activity (P = 0.08, middle), and autonomous/full activity (**P = 0.01, right) in hearts from STZ- (n = 6) and vehicle-treated mice (n = 4). 
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ox-CaMKII was associated with SND in patients and caused SND 
in mice infused with angiotensin II (17). Based on the apparent 
relationship between ox-CaMKII and SND, we next asked whether 
ox-CaMKII was elevated in myocardia from diabetic patients and 
mice. We measured ox-CaMKII using an antiserum against oxi-
dized methionines (methionines 281/282) (15, 17) from right 
atrial samples, nearby to the SAN. We found significantly increased 
expression of ox-CaMKII in myocardia from patients with a history 
of MI and diabetes compared with that in patients with a history 
of MI but without diabetes (Figure 3A and Supplemental Table 
3). Similarly, ox-CaMKII was significantly increased in right atrial 
and SAN tissues from STZ-treated diabetic mice compared with 
those from nondiabetic mice (Figure 3, B and C). In contrast to 
the changes in ox-CaMKII, total right atrial CaMKII expression was 
Figure 4
Oxidation-resistant CaMKII and myocardial CaMKII inhibition protects against SAN cell death and fibrosis. (A) Representative immunoblots and 
Coomassie-stained gels from right atria of STZ-treated MM-VV and WT mice. CaMKII (**P = 0.001), ox-CaMKII (***P ≤ 0.001), and ox-CaMKII/
CaMKII (*P = 0.002) in MM-VV (n = 5) and WT STZ-treated mice (n = 4). (B) Representative immunofluorescence images of SAN from MM-VV and 
WT STZ-treated mice. Scale bars: 50 μm. CaMKII (P = 0.09) and ox-CaMKII (*P = 0.02) in MM-VV (n = 4) and WT STZ-treated mice (n = 5). HCN4 
(green) marks SAN, and DAPI (blue) marks nuclei. (C) Representative SAN sections show TUNEL-positive staining (72) in WT mice after vehicle 
or STZ treatment and in MM-VV and AC3-I mice after STZ treatment. DAPI (blue) marks nuclei, HCN4 (green) marks SAN. Scale bars: 50 μm. 
Overall P < 0.0001, ***P < 0.001 by 1-way ANOVA (n = 3–5 per group). (D) Caspase-3 activity in SAN from WT mice after vehicle or STZ treatment 
and in MM-VV and AC3-I mice after STZ treatment. Overall P = 0.007, *P < 0.05, **P < 0.01 by 1-way ANOVA (n = 3 per group). (E) Representative 
Masson’s trichrome staining for fibrosis in SAN from STZ-treated WT, MM-VV, and AC3-I mice. Scale bars: 20 μm. Overall P = 0.005, **P < 0.01, 
***P < 0.001 by 1-way ANOVA (n = 3–4 per group). 
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equivalent in patients with or without diabetes and in diabetic and 
nondiabetic mice (Figure 3, A–C), suggesting that diabetes predom-
inantly affects CaMKII by posttranslational activation. ox-CaMKII 
is constitutively active, even in the absence of Ca2+/calmodulin (15), 
so we next tested whether increased ox-CaMKII resulted in more 
Ca2+/calmodulin-autonomous CaMKII activity. As expected, the 
cardiac lysates from STZ-treated diabetic mice had significantly 
increased Ca2+- and calmodulin-independent autonomous CaMKII 
activity compared with vehicle-treated control hearts (Figure 3D). 
These findings show that ox-CaMKII is increased in diabetic hearts 
from patients and mice. The parallel increases in ox-CaMKII in 
myocardial tissues from diabetic mice and patients suggest that ox-
CaMKII may contribute to high mortality rates in diabetic patients 
who suffer from MI, potentially by inducing SND.
STZ-treated mice had SND but did not die spontaneously over 
the time course of our study, suggesting that MI may trigger more 
extensive SND by enhancing SAN oxidation. To test this idea, we 
measured SAN oxidation in STZ- and vehicle-treated mice with 
and without MI. We found that STZ treatment alone markedly 
increased SAN ROS, as detected by the ROS fluo rescent indicator 
dihydroethidium (DHE), while MI approximately doubled the 
intensity of DHE fluorescence and ox-CaMKII in STZ-treated 
Figure 5
SAN cell death and fibrosis lead to decreased conduction velocity and spontaneous beating. (A) Cell loss data from vehicle- and STZ-treated 
WT mice were incorporated into a 2-dimensional histologically reconstructed mathematical model of the intact sinoatrial node (action potentials 
from central [Cen] and peripheral [Per] SAN and right atrium are shown). The STZ model with 19% cell loss in the SAN predicts a shift of lead 
pacemaker site (red asterisks on action potential traces), slowing of conduction time and block (double red lines on action potential traces), 
and decreased heart rate similar to experimental measurements. Red arrows denote direction of action potential propagation. (B) Mouse atria 
prepared for optical measurements (left). Original magnification, ×20. Representative pseudocolored isochrones from optical mapping (middle 
and right). SVC, superior vena cava; AVN, atrioventricular node; IVC, inferior vena cava; LA, left atrium; RA, right atrium; LV, left ventricle; RV, 
right ventricle; CT, crista terminalis. White asterisks denote the earliest activation in the SAN. (C) Conduction velocity during pacing in STZ- and 
vehicle-treated mice in the absence (**P = 0.004; n = 5 per group) and presence of isoproterenol (3 nM, *P = 0.01; n = 5 per group). (D) Heart 
rate in isolated atria in the absence (*P = 0.03; n = 4–5 per group) or presence of isoproterenol (ISO; 3 nM, **P = 0.0056; n = 4–5 per group).
Downloaded on October 19, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/65268
research article
1268 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 3   March 2013
mice compared with vehicle-treated mice (Supplemental Figure 
4, A and B), suggesting that MI and diabetes independently pro-
mote oxidation in SAN.
Oxidation-resistant CaMKII eliminates increased mortality from STZ 
after MI. The MM-VV mutation in CaMKIIδ selectively disables oxi-
dative activation of CaMKII without affecting normal Ca2+/calm-
odulin-dependent CaMKII activation or the transition to Ca2+/
calmodulin-independent activation by threonine 287 autophos-
phorylation (15). The MM-VV mice (Supplemental Figure 5) had 
an increase in blood glucose after STZ treatment (Supplemental 
Figure 1) and an increase in ROS in right atrial tissues, as mea-
sured by DHE (Supplemental Figure 6), that was equivalent to that 
in WT STZ-treated mice, but MM-VV STZ-treated mouse hearts 
had significantly less ox-CaMKII expression compared with STZ-
treated WT controls in right atrial tissues (Figure 4A) and SAN 
(Figure 4B). Although MM-VV mice without STZ treatment had 
similar survival after MI compared with WT mice (Supplemental 
Figure 2B), the MM-VV diabetic mice were significantly resistant 
to increased mortality after MI compared with WT diabetic con-
trols (Figure 1A), despite similar left ventricle contractile function 
and volumes after MI compared with WT diabetic mice (Supple-
mental Figure 7). The MM-VV STZ-treated mice were resistant to 
SND after MI, with improvement in resting heart rate (Figure 1D), 
reduced episodes of very low heart rate (<200 beats per minute) 
(Figure 1E), and improved activity-related heart rate increases (Fig-
ure 1F) compared with STZ-treated WT controls after MI. The dis-
tribution of spontaneous activity was similar between MM-VV and 
WT diabetic mice after MI (Supplemental Figure 3), further sug-
gesting that improved survival in MM-VV mice was not due to gen-
erally improved well-being or enhanced myocardial function. We 
next measured the effects of STZ treatment without MI on SAN 
function, in the absence of autonomic innervation, using Lan-
gendorff-perfused hearts isolated from MM-VV and WT control 
mice. Hearts from the STZ-treated MM-VV diabetic mice showed 
improvement in intrinsic sinus node function, as measured by 
increased spontaneous heart rate (Figure 2A), decreased CSNRT 
Figure 6
Mitochondrial ROS increases ox-CaMKII and SAN cell death. (A–C) SAN staining from WT mice treated with STZ alone and MitoTEMPO and STZ 
and Ncf1–/– mice treated with STZ. DAPI (blue) marks nuclei, HCN4 (green) marks SAN. Scale bars: 50 μm. (A) Representative sections show ox-
CaMKII expression. Overall P = 0.006, **P < 0.01 by 1-way ANOVA (n = 3–5 per group). (B) Representative sections show TUNEL-positive cells. Overall 
P = 0.0006, ***P < 0.01 by 1-way ANOVA (n = 3–7 per group). (C) Fibrosis measured by Masson’s trichrome staining. Overall P = 0.016, *P < 0.05 by 
1-way ANOVA (n = 3–4 per group). (D) Proposed model for CaMKII activation by STZ-induced diabetes. STZ-induced hyperglycemia and MI promote 
mitochondrial ROS generation, which activates ox-CaMKII to cause SND, leading to increased mortality after MI.
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(Figure 2B), and improved heart rate responses to isoproterenol 
(Figure 2C), compared with WT diabetic mice. These results show 
that selective ablation of methionines 281/282 on CaMKIIδ is suf-
ficient to protect against STZ-induced oxidant SAN injury and to 
indicate that oxidation of CaMKIIδ is required for excess mortality 
in mice with diabetes after MI.
CaMKII inhibition protects against SND and mortality. The MM-VV 
knockin mutation occurs in all tissues expressing CaMKIIδ, so 
it is possible that the improved SAN function and improved 
survival in these mice were due to unanticipated extra-myocar-
dial effects of oxidation-resistant CaMKIIδ. With this thought 
in mind, we next asked whether cardiac-selective CaMKII inhi-
bition was sufficient to prevent increased mortality and SND in 
STZ-treated mice after MI. We subjected transgenic mice with 
myocardial- (21) and SAN-delimited (17) transgenic expression 
of AC3-I, a synthetic peptide with inhibitory activity against all 
CaMKII isoforms, to MI surgery after STZ or vehicle injection. 
Similar to the MM-VV mice, the AC3-I diabetic mice had sig-
nificant improvement in survival after MI (Figure 1A), without 
showing evidence of improved left ventricle contractile function 
or different left ventricular volumes compared with those of 
WT diabetic mice (Supplemental Figure 7). These findings sug-
gest that improved survival was not due to improvement in left 
ventricular structure or function. AC3-I diabetic mice were also 
resistant to SND, as shown by improvement in resting heart rate 
(Figure 1D), reduced episodes of severe heart rate slowing (Fig-
ure 1E), and increased activity-responsive increases in heart rate 
(Figure 1F), after MI compared with WT diabetic mice after MI. 
We next examined SAN function in STZ-treated AC3-I and WT 
control hearts in the absence of MI. Langendorff-perfused hearts 
isolated from AC3-I diabetic mice showed improvement in intrin-
sic sinus node function, as measured by increased spontaneous 
heart rates (Figure 2A) and decreased CSNRT (Figure 2B), com-
pared with those from WT diabetic mice. The response in heart 
rate to isoproterenol in AC3-I hearts was blunted (Figure 2C), as 
expected based on the role of CaMKII to promote β adrenergic 
receptor agonist increases in heart rate (34). These results suggest 
that myocardial- and SAN-selective CaMKII inhibition protects 
against SND and excessive mortality after MI in diabetic mice.
We next asked whether SAN-targeted CaMKII inhibition was suf-
ficient to prevent SND in the absence of “global” cardiac CaMKII 
inhibition. We used a SAN-targeted gene transfer technique (17) 
to deliver the most potent and selective known biological CaMKII 
inhibitor, CAMKIIN, a peptide that is endogenously expressed in 
brain but not in heart (35). Adenovirus encoding CaMKIIN and 
EGFP or an adenovirus encoding EGFP alone was painted on 
SAN of WT mice treated with STZ. Langendorff-perfused hearts 
isolated from diabetic mice after SAN painting with adenovirus 
expressing CaMKIIN and EGFP, compared with those painted 
with adenovirus expressing EGFP alone, showed improved resting 
heart rate (Figure 2D) and reduced CSNRT (Figure 2E). Similar 
to that in AC3-I hearts, the response in heart rate to isoproterenol 
in mice with SAN CaMKIIN expression was blunted (Figure 2F). 
These data confirm that SAN-targeted CaMKII inhibition protects 
against diabetes-induced SND.
Diabetes causes SND by CaMKII-triggered SAN cell apoptosis and fibro-
sis. Cardiomyocyte apoptosis and ROS are increased in diabetes 
but the molecular mechanism for connecting increased oxidant 
stress to diabetes-mediated apoptosis is uncertain (36, 37). Exces-
sive ox-CaMKII activity also promotes apoptosis, leading to mal-
adaptive cardiovascular responses to injury, including SND (15, 
17). The SAN consists of a small group of highly specialized pace-
maker cells that reside in the lateral right atrium. The relatively 
small number of cells in the SAN, compared with the larger num-
ber of contracting myocardial cells, make physiological SAN func-
tion particularly vulnerable to SAN cell death; SND occurs when 
SAN cell loss exceeds a threshold value, leading to a source-sink 
mismatch between SAN and surrounding atrial myocardium (17). 
We found significantly increased TUNEL staining and caspase-3 
activity, indicating increased cell death, in right atrial tissues con-
taining SAN (Figure 4, C and D) from diabetic mice compared 
with those from nondiabetic mice. In contrast, MM-VV and AC3-I 
mice were resistant to diabetes-induced increases in TUNEL stain-
ing and caspase-3 activity (Figure 4, C and D). MM-VV and AC3-I 
mice treated with STZ and subjected to MI were protected from 
SAN apoptosis compared with WT controls (Supplemental Figure 
8). These findings are consistent with a concept that SND arises 
from STZ and MI as a form of oxidant injury that requires SAN 
ox-CaMKII–mediated SAN cell death.
SAN tissue from patients with SND is also marked by increased 
fibrosis and destruction of normal architecture that may contrib-
ute to conduction slowing and defective impulse transmission 
(32, 38). In order to test whether diabetes causes SAN fibrosis 
characteristic of patients with SND, we quantified SAN and atrial 
collagen by Masson’s trichrome staining. Collagen expression 
within the SAN was higher in diabetic mice compared with that 
in nondiabetic mice (Figure 4E). In contrast, MM-VV and AC3-I 
diabetic mice did not exhibit increased fibrosis (Figure 4E). Taken 
together, these data show that diabetes promotes ox-CaMKII, SAN 
cell apoptosis, fibrosis, and SND.
In order to quantify the contribution of SAN cell death to SND 
in our STZ and MI model, we incorporated measured values for 
SAN cell loss from nondiabetic and diabetic mice into a 2-dimen-
sional computational model of SAN, based on histologically 
reconstructed right atrial geometry (17). Normal activation of the 
atrial myocardium (vehicle treated in Figure 5A) was triggered by 
a regular impulse that initiates in the central SAN. Our mathe-
matical model revealed that increased cell loss in diabetic hearts 
greatly disrupted the normal capture of atrial myocardium by 
SAN impulses. Specifically, the model with increased cell loss dis-
played a shift of the lead pacemaker site toward the SAN periph-
ery, a delay in conduction time from the SAN to the atrial myo-
cardium, and slowing of heart rate comparable to experimentally 
measured values (Figure 5A and Supplemental Videos 1 and 2). 
Thus, our mathematical model of the intact SAN predicts that 
cell loss alone can produce SND characterized by slowed heart 
rate. We next measured spontaneous impulse formation in cur-
rent-clamped SAN cells isolated from diabetic and vehicle-infused 
control mice. SAN cells from both groups showed similar sponta-
neous automaticity at baseline and in response to isoproterenol 
(Supplemental Figure 9), suggesting that SAN cell loss in STZ-
treated mice, rather than defects in the function of surviving SAN 
cells, was the primary cause of STZ-induced SND. Thus, compu-
tational and experimental analyses support a view that excessive 
SAN cell death is a fundamental event causing increased mortal-
ity after MI in the setting of diabetes.
Patients with SND exhibit widespread atrial electrophysiologi-
cal abnormalities secondary to destruction of normal SAN archi-
tecture, leading to slowed conduction velocity (32). To determine 
whether STZ-induced diabetes slowed conduction velocity, we 
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performed potentiometric optical mapping in isolated atria from 
STZ- and vehicle-treated mice. To control for differences in intrin-
sic heart rate between STZ- and vehicle-treated mice, we measured 
conduction velocity in isolated atria during fixed rate stimulation. 
We found significantly decreased conduction velocity in STZ-
treated mice compared with that in control mice in the absence 
and presence of isoproterenol (Figure 5C). In addition, heart rates 
were significantly slower in isolated atria from diabetic hearts 
compared with nondiabetic counterparts (Figure 5D). Further-
more, atria isolated from STZ-treated mice also showed impaired 
responses to isoproterenol (Figure 5D). Taken together, these find-
ings support a view that STZ treatment resulted in SND that was 
caused, at least in part, by intrinsic defects in SAN function. Our 
optical mapping studies (Figure 5, B and C) and computational 
modeling (Figure 5A) also support the concept that atrial myo-
cardium is injured by STZ treatment, as evidenced by decreased 
conduction velocity measured throughout the atrial tissues.
Mitochondria are the source of ROS for increasing ox-CaMKII in 
diabetes and MI. Diabetes is known to increase ROS production 
in mitochondria and apoptosis in cardiomyocytes (11, 36, 37), 
but to our knowledge mitochondrial ROS generation has not 
been linked to SND in diabetes. To determine whether diabetes 
causes SND by enhancing mitochondrial ROS generation and 
SAN ox-CaMKII, we implanted mice with osmotic mini-pumps 
eluting MitoTEMPO (700 μg/kg/d), a mitochondrial targeted 
ROS scavenger with generalized antioxidant activities, including 
superoxide dismutase (39, 40), immediately prior to STZ treat-
ment. The ROS levels measured by DHE (Supplemental Figure 
10) and ox-CaMKII levels were significantly reduced in SAN from 
MitoTEMPO-treated mice compared with those in control dia-
betic mice (Figure 6A). MitoTEMPO-treated diabetic mice had 
significantly fewer TUNEL-stained SAN cells (Figure 6B) and 
decreased fibrosis compared with control diabetic mice (Figure 
6C). p47phox encodes a cytosolic regulatory subunit of NADPH 
oxidase, a multicomponent ROS-generating enzyme complex. 
Angiotensin II, aldosterone, and MI all increase ox-CaMKII, at 
least in part, by activating a p47phox containing NADPH oxidase 
(15–17). In contrast, STZ treatment does not appear to increase 
ox-CaMKII by activating NADPH oxidase, because Ncf1–/– 
(p47phox–/–) STZ-treated mice were not protected from increases 
in ox-CaMKII or SAN cell apoptosis and fibrosis after MI (Figure 
6, A–C). MitoTEMPO-treated diabetic mice, but not Ncf1–/– dia-
betic mice, had improved survival after MI (Figure 1A), despite 
similar left ventricle contractile function and chamber volumes 
after MI compared with WT diabetic mice (Supplemental Figure 
7). MitoTEMPO-treated diabetic mice, but not Ncf1–/– diabetic 
mice, were also resistant to SND, as evidenced by improvement 
in heart rate at rest (Figure 1D), significantly decreased episodes 
of heart rate ≤200 beats per minute (Figure 1E), and enhanced 
heart rate response to activity (Figure 1F) after MI compared 
with WT diabetic mice. We examined the effects of STZ treat-
ment without MI in the absence of autonomic innervation using 
Langendorff-perfused hearts isolated from MitoTEMPO- and 
STZ-treated WT mice and STZ-treated Ncf1–/– mice. MitoTEMPO 
infusion improved heart rates (Figure 2A), normalized CSNRT 
(Figure 2B), and restored control level heart rate responses 
to isoproterenol (Figure 2C) compared with WT diabetic and 
Ncf1–/– diabetic mice. In contrast, Ncf1–/– diabetic mice had heart 
rate responses similar to those of WT diabetic mice (Figure 2C). 
We interpret these data to indicate that mitochondrial gener-
ated ROS is required for diabetes-induced ox-CaMKII elevation, 
increased SAN cell death, and SND and to suggest that multi-
ple, injury-specific sources of ROS have the potential to oxidize 
CaMKII and induce pathological consequences in heart.
Based on the requirement for increased glucose for SND phe-
notypes (Figure 1, D–F), we next used cultured neonatal myo-
cytes to determine whether elevated glucose was sufficient to 
increase mitochondrial ROS and/or apoptosis. Neonatal myocytes 
responded to high glucose (33 mM), a concentration similar to 
the elevated plasma glucose levels in diabetic mice, with increased 
ROS and apoptosis (Supplemental Figure 11). In contrast, neither 
a lower glucose concentration (5 mM) nor mannitol (33 mM), a 
metabolically inert glucose congener, increased ROS or apoptosis. 
ROS and apoptosis were reduced by MitoTEMPO (1 mM) (Sup-
plemental Figure 11). Neonatal cardiomyocytes isolated from 
MM-VV mice responded to high glucose treatment with increased 
ROS but not apoptosis (Supplemental Figure 11). These findings 
support the hypothesis that hyperglycemia in diabetic mice stimu-
lates mitochondrial ROS production, leading to apoptosis.
Discussion
Elevated ROS is a consistent finding in cardiovascular diseases, 
but understanding of defined molecular targets and pathways 
that connect increased oxidation with disease phenotypes is 
limited (11, 14, 38, 41). Here we show that selective ablation of 
oxidative activation of CaMKIIδ was sufficient to eliminate the 
increased risk of sudden death in diabetic mice after MI. The 
hearts from MM-VV diabetic mice exhibited a normal heart rate 
response to isoproterenol, showing that oxidation of CaMKII is 
not required for fight-or-flight physiological responses and sug-
gesting that β adrenergic receptor activation was not a decisive fac-
tor in oxidative injury for STZ-treated mice after MI. Our MM-VV 
mutant mouse only targeted the CaMKIIδ isoform. The finding 
that ox-CaMKIIδ–resistant MM-VV mice were not susceptible to 
STZ-induced SND or increased mortality after MI is potentially 
consistent with recent studies showing that CaMKIIδ–/– mice with 
residual CaMKII activity, presumably due to CaMKIIδ-alternative 
CaMKII isoforms, were nevertheless resistant to cardiac injury (19, 
20). Our studies identified SAN as a critical target of a novel and 
unanticipated oxidation-sensitive molecular pathway underlying 
increased mortality after MI in diabetic mice. This ox-CaMKII 
pathway may also increase mortality risk in diabetic patients, who 
show more severe heart rate defects consistent with SND (22, 23, 
31) and higher right atrial ox-CaMKII than nondiabetic patients 
after MI. Because multiple tissues are injured in diabetes, it will 
be important to learn if ox-CaMKII contributes to progression of 
diverse forms of diabetic injury, such as diabetic vasculopathy and 
neuropathy. It is intriguing that CaMKII inhibition was recently 
found to improve insulin sensitivity in diabetes (42), suggesting 
that CaMKII inhibition could benefit diabetic patients by multiple 
mechanisms and pathways.
Increased rates of sudden cardiac death after MI in diabetic 
patients are due to arrhythmia (4, 6, 8, 30), and some data suggest 
excessively slow heart rates contribute to this excess mortality. For 
example, among the 41,021 patients of the GUSTO-I cohort, a 
study demonstrating that diabetic patients had increased mortal-
ity after acute MI despite contemporary thrombolysis, the rates of 
bradycardia were consistently higher among diabetic patients (6). 
Furthermore, loss of heart rate variability, a marker of SAN and 
autonomic nerve function that is defective in diabetic patients, 
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positively correlates with increased acute mortality after MI (43). 
Although reduced heart rate variability, a feature of SND, could be 
due to intrinsic SAN defects, loss of normal autonomic function, 
or a combination of both, our ex vivo findings indicate that STZ 
treatment directly affects SAN, causing intrinsic SND by increased 
apoptosis, fibrosis, and subsequent electrical source-sink mis-
match between SAN and myocardium. Our findings do not dis-
pute a role for autonomic dysfunction in diabetes-induced defects 
in heart rate but appear consistent with other evidence showing 
diabetes causes pathological effects on SAN (44–46).
Our findings suggest that SAN injury induced by hyperglyce-
mia sensitizes the SAN to MI-induced dysfunction, as evidenced 
by profoundly slow heart rates, low cardiac output, and death. 
Our study suggests that MI aggravates SND by further increasing 
ROS, ox-CaMKII, and apoptosis of SAN cells in diabetic mice. We 
conclude that increased acute mortality after MI in diabetic mice 
is primarily caused by SND, but our findings do not exclude the 
possibility of other contributing factors. For example, left ventric-
ular end diastolic volumes in our diabetic mice did not increase, 
despite increased filling time as a result of profound bradycardia 
(Supplemental Table 2), suggesting that STZ-treated mice after MI 
have diastolic dysfunction, a recognized feature of diabetic cardio-
myopathy (47). Furthermore, MI activates a multitude of neuro-
humoral factors, including the renin-angiotensin system, which 
could also contribute to SND (17).
Clinical trials have shown that optimal glucose management 
reduces mortality from cardiovascular diseases in diabetic patients 
(48, 49). However, the more recent ACCORD study reported con-
flicting results, which indicated that intensive glucose lowering 
was not beneficial for cardiovascular mortality (50). Nevertheless, 
meta-analysis on major randomized trials, including the ACCORD 
study, concluded that intensive control groups (0.9% A1C reduc-
tion over 5 years) significantly reduced events of nonfatal MI by 
17% and coronary heart disease by 15% (51). It appears that the 
glucose level itself, not the form of glucose intolerance, may be 
the key driver of mortality risk in diabetic patients suffering from 
MI. In support of this view is a meta-analysis report in which non-
diabetic patients presenting with hyperglycemia had a similar 
risk of mortality as that for diabetic patients after MI (52). Our 
studies showed that increased diabetes-attributable mortality in 
STZ-treated mice was prevented after insulin replacement, demon-
strating that hyperglycemia rather than off-target actions of STZ 
caused increased mortality after MI. Our study used an STZ-in-
duced model of type 1 diabetes with severe hyperglycemia. This 
model is limited, as it lacks the metabolic complexity of type 2 
diabetes, a condition that represents the majority of the diabetic 
population. The hyperglycemia level in STZ-treated mice may not 
mimic the levels in the diabetic population exactly. Nevertheless, 
the STZ model of type 1 diabetes allows a clear focus on the role of 
hyperglycemia, which is the key metabolic alteration in both type 
1 and type 2 diabetes.
Despite of the availability of insulin therapy, glycemic control 
remains a major challenge in diabetes management (53, 54). Inad-
equate glycemic control likely accounts for the high prevalence of 
diabetic complications, such as MI, and the associated significant 
morbidity and mortality. Hyperglycemia is common in patients 
with MI and tends to persist throughout the early period after 
infarction (55–57). For example, in a study of approximately 
30,000 patients admitted to hospitals with acute MI, about half of 
the patients were hyperglycemic and had significantly higher mor-
tality early after MI compared with their normoglycemic counter-
parts (52, 56). We interpret the data from our human specimens to 
show that increased ox-CaMKII may be a feature of human diabe-
tes in the setting of MI but recognize that our data set is not ade-
quately powered for subgroup analysis. We also acknowledge the 
limitations of this study using patient samples with an antecedent 
MI in the context of focusing on ox-CaMKII in mice in the peri-
MI setting. Nevertheless, our observations suggest that increased 
ox-CaMKII may be a marker of poor glycemic control in patients 
with coronary artery disease. Therefore, it is possible that the ben-
efits of glucose control are due, at least in part, to reduction in 
ox-CaMKII.
Increased oxidative stress brought about by hyperglycemia is 
an important link between diabetes and its cardiac complications 
(11, 12). Until now, the cellular source of ROS known to oxidize 
CaMKII was NADPH oxidase (15–17). Here we show that STZ 
treatment increased ox-CaMKII by augmenting mitochondrial 
ROS, apparently independent of NADPH oxidases. Increased 
glucose in vivo, due to STZ treatment, or in vitro was required to 
increase ROS, while infused MitoTEMPO effectively suppressed 
hyperglycemia-induced ROS, SND, and sudden death. Mitochon-
dria constitutively generate superoxide radicals as a by-product of 
electron transport and are also important sources for intracellular 
ROS production triggered by hyperglycemia (58, 59). Our current 
findings, taken together with earlier studies (15–17), suggest that 
CaMKII is available for oxidation by multiple pathways. The find-
ing that myocardia from STZ-treated MM-VV mice had equivalent 
increases in ROS compared with controls shows that ox-CaMKIIδ 
is downstream to ROS for causing SND and increased mortality 
after MI. However, CaMKIIγ has been implicated in enhancing 
mitochondrial Ca2+, a process that could potentially promote mito-
chondrial ROS generation (60), and we recently found that CaMKII 
increased mitochondrial Ca2+ entry by activating the mitochondrial 
Ca2+ uniporter (61). Thus, it is possible that CaMKII contributes to 
ROS generation after STZ treatment, functioning as an “upstream” 
and “downstream” signal in oxidative injury. The trend toward 
reduced STZ-induced ROS in AC3-I mice (Supplemental Figure 6) 
is potentially consistent with this concept, because AC3-I inhibits 
all CaMKII isoforms. We used AC3-I mice to compare the effects of 
global myocardial CaMKII inhibition with MM-VV mice that are 
selectively protected from oxidative activation of CaMKIIδ.
We originally identified ox-CaMKII in response to angiotensin II 
stimulation of myocardium (15). The renin-angiotensin system is 
activated in diabetes, and angiotensin II inhibition was shown to 
be even more beneficial in improving mortality after MI in diabetic 
patients than in nondiabetic patients (62, 63). Both angiotensin II 
antagonists (62, 63) and anti-hyperglycemic therapy (51) improve 
mortality in diabetic patients after MI. These data from clinical trials 
raise the issue of whether some of the benefits of validated, conven-
tional therapies for diabetes work by reducing ox-CaMKII. Our find-
ings are consistent with the idea that ox-CaMKII could be a “diabetic 
factor” and suggest that CaMKII inhibition or antioxidant therapy 
targeted to CaMKII or mitochondria could be effective preventive 
therapies for diabetic patients at high risk for MI.
Methods
Mouse models. We performed our studies on male and female mice with 
C57BL/6 backgrounds at approximately 3–5 months of age. Mice lacking 
the Ncf1 gene (Ncf1–/– mice) were purchased from The Jackson Laboratory. 
Mice with transgenic myocardial CaMKII inhibition (AC3-I mice) were 
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(34). ECGs were continuously recorded with Ag+/AgCl electrodes posi-
tioned around the hearts in an approximate Einthoven configuration, as 
previously described (17). Langendorff-perfused hearts were stimulated 
with a pair of electrodes placed on the right atrium. Sinus node recovery 
time was measured after a 30-second pacing train, with a basic cycle length 
of 100 ms. For these studies, the sinus node recovery time was defined as 
the interval between the last stimulus in the pacing train and the onset 
of first sinus return beat. The CSNRT was calculated by subtracting the 
baseline cycle length from the sinus node recovery time.
SAN and atrial optical mapping. Optical mapping of spontaneous pacemaker 
activity and conduction velocity were performed as described previously (17).
SAN tissue isolation. Mice were sacrificed, and hearts were excised and 
placed in Tyrode’s solution (35°C), consisting of 140 mM NaCl, 5.0 mM 
HEPES, 5.5 mM glucose, 5.4 mM KCl, 1.8 mM CaCl2, 1.0 mM MgCl2, with 
pH adjusted to 7.4 with NaOH. The SAN region, delimited by the crista ter-
minalis, atrial septum, and orifice of the superior vena cava, was dissected 
from the heart as previously described (17).
Immunofluorescence staining and SAN identification. The SAN tissues were 
cryopreserved and sectioned at 14-μm thickness. We used anti-HCN4 
antibodies to identify the SAN region (34). For all immunofluorescence 
staining, the slides were fixed and incubated with a blocking buffer and 
subsequently with the primary antibody to the protein of interest (rab-
bit anti-mouse ox-CaMKII and mouse anti–C-terminal CaMKII antibod-
ies were developed by us) with HCN4 antibody (rat anti-human HCN4, 
Abcam), as previously described (17). For TUNEL staining, tissues were 
incubated using the In Situ Cell Death Detection Kit (Roche) for 1 hour 
at 37°C, washed with PBS, and then mounted with DAPI Vectashield 
Medium (Vector Laboratories).
Immunoblotting. SAN tissues were homogenized in modified RIPA buffer 
(50 mM HEPES, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% v/v NP-40, and 
0.5% w/v deoxycholate), containing a mixture of protease and phosphatase 
inhibitors. Equal amounts of protein were loaded on NuPAGE gels 
(Invitrogen) and transferred onto PVDF membranes (Bio-Rad). Blots were 
blocked, incubated in primary antibodies (ox-CaMKII and CaMKII) and 
subsequently with HRP-conjugated secondary antibodies, and finally 
detected using ECL reagent (Lumi-Light, Roche) as previously described 
(17). For quantification, band intensity was normalized to the entire 
Coomassie-stained gel using ImageJ software (NIH). Full uncut gels are 
shown in the Supplemental Material.
ROS detection. After cells or SAN sections were washed in warm PBS, DHE 
was applied for 30 minutes at 37°C, as previously described (16). Fluorescence 
was detected with a laser scanning confocal microscope (Zeiss 510 and 710; 
excitation at 488 nm and detection at 585 nm by using a long-pass filter).
Caspase-3 activity assay. SAN tissue was homogenized in lysis buffer con-
sisting of 50 mM Tris-HCl, pH 7.5, 100 mM KCl, 1 mM EDTA, 1 mM EGTA, 
1 mM DTT, 0.1 mM PMSF, 0.5 mM benzamidine, 20 mg/l leupeptin, 1,000 
mM microcystin, 20 mM sodium pyrophosphate, 50 mM NaF, and 50 mM 
sodium β-glycerophosphate, and total protein content was determined by 
the Bradford assay. Caspase-3 activity was determined by the EnzChek Cas-
pase-3 Assay Kit (Invitrogen) as previously described (17).
Fibrosis detection and quantification. Masson’s trichrome staining was used 
to assess fibrosis. We defined the SAN by HCN4-positive immunostaining 
(34). The images were imported into ImageJ (NIH), and the pixels of blue 
staining were analyzed in the intranodal region (within the core SA node).
Isolated SAN cell action potential recording. SAN cells were isolated, and sponta-
neous single cell action potentials were recorded in current clamp mode using 
the perforated patch configuration at 36°C, as described previously (34).
Neonatal cardiomyocyte culture. Hearts were digested with trypsin and col-
lagenase II, incubated in media consisting of 40% F10, 40% DMEM, 5% 
FBS, 5% ES for 24 hours, then in defined media for 24 hours as previously 
generated by us, as previously described (21). MM-VV mice were gener-
ated as follows (Supplemental Figure 5): the 2 homologous arms, left arm 
(LA, containing exons 9–12) and right arm (RA, containing exon 13), were 
directly amplified via high-fidelity PCR using the genomic DNA prepared 
from a murine ES cell strain W4 (129/SvEvTac). The mutations were cre-
ated in exon 11 of LA. The LA and RA were cloned into OSDupDel.Neo, 
a generic targeting vector containing both Lox-P–flanked Neo cassette 
(MC1-Neo) and thymidine kinase cassette (PGK-TK) to obtain a final tar-
geting construct. The targeting construct linearized with NotI was elec-
troporated into W4 cells. After selection with G418, targeted homologous 
replacement recombinants were identified by specific PCRs and by DNA 
sequencing. The confirmed ES cell lines were microinjected into C57BL/6J 
blastocysts (Uteri transfer) to obtain chimeras that were crossed with 
C57BL/6J to verify germ line transmission. The transmitted germ lines 
were mated with EIIa-Cre Tg mice (C57BL/6J, The Jackson Laboratory) to 
obtain final allele with Neo cassette removal. These heterozygote mice (64) 
were bred to obtain homozygote knockin mice identified by PCR genotyp-
ing using tail DNA.
STZ-induced diabetic model. After overnight fast, mice were injected 
intraperitoneally with streptozocin (150 mg/kg, Sigma-Aldrich) dissolved 
in a mix of citrate buffer (citric acid and sodium citrate, pH 4.8) or vehicle 
(citrate buffer). Blood glucose was checked 3–5 days later via tail vein; mice 
with a blood glucose level above 300 mg/dl were considered diabetic. For a 
subset of animals, long acting insulin (Lantus) was injected subcutaneously 
every 24 hours 3–5 days after STZ treatment to maintain normoglycemia.
MI and ECG and activity telemetry. Mice were anesthetized with ketamine/
xylazine (87.5/12.5 mg/kg), and left anterior descending artery was ligated 
with 8-0 suture, as previously described (15). Sham surgery was conducted 
by thoracotomy without LAD ligation. Cardiac rupture was identified by 
blood clotting in the chest cavity and ventricular wall tearing. ECG trans-
mitters (Data Sciences International) were inserted into the abdominal 
cavity with subcutaneous electrodes in a lead I configuration. Upon recov-
ery from surgery, continuous 24-hour recordings were started and contin-
ued for 1 week or sooner if mice died. At the end of each experiment, the 
data were extracted and analyzed for resting heart rate (defined as heart 
rate when activity was 0), heart rate response to activity, and arrhythmias. 
We defined spontaneous SND episodes as events of severe bradycardia, 
with heart rates of less than 200 beats per minute.
Mini-osmotic pump implantation. Micro-osmotic pumps (Alzet model 1004, 
0.11 μl/h, 28 days) containing MitoTEMPO (700 μg/kg/d) were inserted 
subcutaneously into mice under anesthesia (ketamine/xylazine, 87.5/12.5 
mg/kg), as reported previously (15).
Transthoracic echocardiography. We recorded transthoracic echocardio-
grams in conscious mice after MI, as previously described (65). Images 
were acquired and analyzed by an operator blinded to mouse genotype 
and treatment.
Human samples. Right atrial tissues were obtained from patients who 
had MI, with or without diabetes (Supplemental Table 3), as published 
previously (66).
SAN painting. Mice were painted within 1 week after STZ treatment, 
as previously described (17). Briefly, a mixture of 40% poloxamer, 1% 
trypsin, and 0.25% collagenase dissolved in PBS was added to equal vol-
ume of recombinant adenovirus-expressing plasmid for CaMKIIN-EGFP 
in an IRES vector or EGFP alone. Mice were anesthetized using ketamine/
xylazine (87.5/12.5 mg/kg, respectively). The gel was applied to the pos-
terior surface of the junction of the superior vena cava and right atrium 
with a fine brush 3 times, with intervening periods of drying. Mice were 
sacrificed after 5 to 7 days, and hearts were harvested for ex vivo studies.
Langendorff perfusion and ex vivo ECG recording. Excised hearts were quickly 
mounted on a modified Langendorff apparatus, as described previously 
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